Analysts forecast that Proteostasis Therapeutics Inc (NASDAQ:PTI) will report earnings of ($0.65) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Proteostasis Therapeutics’ earnings, with estimates ranging from ($0.72) to ($0.61). Proteostasis Therapeutics posted earnings of ($0.38) per share in the same quarter last year, which would suggest a negative year over year growth rate of 71.1%. The business is scheduled to issue its next earnings report on Thursday, March 29th.

On average, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($2.47) per share for the current financial year, with EPS estimates ranging from ($2.56) to ($2.40). For the next fiscal year, analysts forecast that the business will report earnings of ($2.21) per share, with EPS estimates ranging from ($2.81) to ($1.49). Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Proteostasis Therapeutics.

Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.16. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%. The business had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.38 million.

A number of equities research analysts recently commented on the stock. Leerink Swann reissued an “outperform” rating and issued a $9.00 price objective (down from $17.00) on shares of Proteostasis Therapeutics in a research note on Wednesday, August 16th. Zacks Investment Research cut shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in shares of Proteostasis Therapeutics by 425.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,124,602 shares of the company’s stock worth $2,361,000 after purchasing an additional 910,550 shares during the last quarter. Bain Capital Public Equity Management LLC acquired a new stake in shares of Proteostasis Therapeutics during the 2nd quarter worth about $1,233,000. Jennison Associates LLC boosted its stake in shares of Proteostasis Therapeutics by 6.2% during the 2nd quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock worth $9,713,000 after purchasing an additional 120,575 shares during the last quarter. FMR LLC boosted its stake in shares of Proteostasis Therapeutics by 2.3% during the 2nd quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after purchasing an additional 66,111 shares during the last quarter. Finally, Sabby Management LLC boosted its stake in shares of Proteostasis Therapeutics by 109.6% during the 2nd quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after purchasing an additional 65,451 shares during the last quarter. 68.08% of the stock is currently owned by hedge funds and other institutional investors.

Proteostasis Therapeutics (NASDAQ PTI) traded down $0.12 during trading hours on Wednesday, hitting $2.41. 65,332 shares of the stock were exchanged, compared to its average volume of 186,912. Proteostasis Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $16.67.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/12/09/proteostasis-therapeutics-inc-pti-expected-to-post-earnings-of-0-65-per-share.html.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteostasis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.